ContractWarrants and Subscription Agreement • November 3rd, 2017 • Brainstorm Cell Therapeutics Inc. • Biological products, (no disgnostic substances)
This 2017 Amendment of Warrants and Subscription Agreement (the “Amendment”) is entered into by and among ACCBT Corp. (“ACCBT”), ACC International Holdings Ltd. (“ACC”, and together with ACCBT and their affiliated entities, the “ACCBT Entities”), and Brainstorm Cell Therapeutics Inc. (the “Company”), dated as of the date executed by the parties hereto, and effective November 5, 2017 (the “Effective Date”). Reference is hereby made to that certain Subscription Agreement by and between ACCBT and the Company, dated as of July 2, 2007 (as amended, the “Subscription Agreement”), a related Registration Rights Agreement between the Company and ACCBT, and any and all issued and outstanding warrants to purchase Company common stock held by the ACCBT Entities as of the date hereof (the “ACCBT Warrants”) and any related documents (all of the foregoing documents together, the “ACCBT Documents”). For the avoidance of doubt, stock options and other compensation issued by the Company to Chaim Lebovit
